Niox Group PLC
LSE:NIOX

Watchlist Manager
Niox Group PLC Logo
Niox Group PLC
LSE:NIOX
Watchlist
Price: 68 GBX 2.41% Market Closed
Market Cap: 284.2m GBX
Section:
 

Relative Value

The Relative Value of one NIOX stock under the Base Case scenario is 60.42 GBX. Compared to the current market price of 68 GBX, Niox Group PLC is Overvalued by 11%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NIOX Relative Value
Base Case
60.42 GBX
Overvaluation 11%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.2
P/S
P/S
Price to Sales
6.2
vs History
58
vs Industry
49
Median 3Y
6.8
Median 5Y
6.2
Industry
8
Forward
6
More Details
54.6
P/E
P/E
Price to Earnings
54.6
vs History
19
vs Industry
6
Median 3Y
26.5
Median 5Y
24.4
Industry
23.5
Forward
26.1
More Details
15.7
P/OCF
P/OCF
Price to OCF
15.7
vs History
71
vs Industry
7
Median 3Y
22.7
Median 5Y
22.1
Industry
21.9
More Details
17.6
P/FCFE
P/FCFE
Price to FCFE
17.6
vs History
69
vs Industry
8
Median 3Y
25
Median 5Y
24.4
Industry
24.3
More Details
4.4
P/B
P/B
Price to Book Value
4.4
vs History
11
vs Industry
25
Median 3Y
3.4
Median 5Y
3
Industry
3.2
More Details
5.9
EV/S
EV/S
Enterprise Value to Sales
5.9
vs History
52
vs Industry
42
Median 3Y
6.3
Median 5Y
5.9
Industry
8.1
Forward
5.7
More Details
8.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
8.3
vs History
55
vs Industry
39
Median 3Y
8.8
Median 5Y
8.3
Industry
10.1
More Details
20.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
20.2
vs History
76
vs Industry
5
Median 3Y
25.2
Median 5Y
25
Industry
5.9
Forward
17.6
More Details
29.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
29.3
vs History
57
vs Industry
3
Median 3Y
45.6
Median 5Y
30.7
Industry
6.2
Forward
25.3
More Details
15.1
EV/OCF
EV/OCF
Enterprise Value to OCF
15.1
vs History
71
vs Industry
8
Median 3Y
20.4
Median 5Y
20
Industry
7.7
More Details
16.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
16.3
vs History
69
vs Industry
6
Median 3Y
20.9
Median 5Y
20.6
Industry
6.3
More Details
4.7
EV/IC
EV/IC
Enterprise Value to IC
4.7
vs History
12
vs Industry
31
Median 3Y
3.9
Median 5Y
3.2
Industry
5.6
More Details

Multiples Across Competitors

NIOX Competitors Multiples
Niox Group PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Niox Group PLC
LSE:NIOX
284.1m GBP 6.2 54.6 20.2 29.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 845 618.3 -160 863.2 -195 339.2 -193 110.2
US
Abbvie Inc
NYSE:ABBV
405.3B USD 6.8 172.6 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
176.3B USD 4.9 25.2 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
151B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 081.5 -531.1 -578.4 -562.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.7B USD 5.7 17.9 17 19.3
AU
CSL Ltd
ASX:CSL
83.3B AUD 3.6 18.6 12.6 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD 16.4 1 210.6 163.2 198
NL
argenx SE
XBRU:ARGX
44.3B EUR 14.4 33.9 58.4 60
P/S Multiple
Revenue Growth P/S to Growth
UK
Niox Group PLC
LSE:NIOX
Average P/S: 3 077 070.3
6.2
12%
0.5
FR
Pharnext SCA
OTC:PNEXF
33 845 618.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 081.5
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
NL
argenx SE
XBRU:ARGX
14.4
49%
0.3
P/E Multiple
Earnings Growth PEG
UK
Niox Group PLC
LSE:NIOX
Average P/E: 175.9
54.6
62%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 863.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
10%
1.8
AU
CSL Ltd
ASX:CSL
18.6
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 210.6
N/A N/A
NL
argenx SE
XBRU:ARGX
33.9
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Niox Group PLC
LSE:NIOX
Average EV/EBITDA: 38
20.2
20%
1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 339.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163.2
N/A N/A
NL
argenx SE
XBRU:ARGX
58.4
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Niox Group PLC
LSE:NIOX
Average EV/EBIT: 44.5
29.3
25%
1.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 110.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -562.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198
N/A N/A
NL
argenx SE
XBRU:ARGX
60
N/A N/A

See Also

Summary
NIOX intrinsic value, competitors valuation, and company profile.
DCF Valuation
NIOX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NIOX stock valuation using valuation multiples.
Wall Street Estimates
NIOX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NIOX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 306,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.